UBS Group
MENS

UBS Group’s Jyong Biotech MENS Stock Holding History

UBS Group’s Portfolio MENS Stock Details MENS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$80.3K Sell
37,363
-108,285
-74% -$265K ﹤0.01% 7101
2025
Q4 		$575K Buy
145,648
+145,111
+27,023% +$5.12M ﹤0.01% 5995
2025
Q3 		$21.1K Buy
+537
New +$19.3K ﹤0.01% 8117

Other funds holding MENS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.32B AUM 51.82% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group's MENS Position: Q1 2026 in Review

UBS Group reduced its Jyong Biotech (MENS) stake by 74% in Q1 2026, selling an estimated $265K and leaving 37,363 shares worth $80.3K. The position accounts for ﹤0.01% of the portfolio, ranked #7101.

UBS Group first reported a position in MENS in Q3 2025 and has held it in 3 quarters since. The position peaked at $575K in Q4 2025. 17 funds tracked by Wall St. Rank hold MENS as of Q1 2026.

  • UBS Group held 37,363 shares of Jyong Biotech worth $80.3K as of Q1 2026.
  • UBS Group sold 108,285 Jyong Biotech shares in Q1 2026, an estimated $265K.
  • Jyong Biotech made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #7101 holding.
  • UBS Group first reported a position in Jyong Biotech in Q3 2025 and has held it in 3 quarters since.
  • UBS Group's Jyong Biotech position peaked at $575K in Q4 2025.
  • 17 funds tracked by Wall St. Rank held Jyong Biotech as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.